Companies

UroGen Pharma Ltd.

URGN · CIK 0001668243 · operating

$19.02-12.35%Last updated Mar 3, 12:10 AM

Key Statistics

Valuation

Market Cap$890.31M
P/E
Fwd P/E14.01
PEG
P/S9.22
P/B
EV/EBITDA-7.77
EV/Rev10.55

Profitability

Gross Margin88.66%
Op. Margin-113.73%
Net Margin-139.81%
ROE145.53%
ROA-76.57%
FCF Margin-148.22%

Financial Health

Current Ratio4.01
Debt/Equity-2.90
Free Cash Flow-$162.73M
Div. Yield

Growth & Other

Revenue Growth346.93%
EPS Growth
Beta1.36
52W High$30
52W Low$3.42

About UroGen Pharma Ltd.

UroGen Pharma Ltd. (URGN) is a pharmaceutical preparations company incorporated in Israel, listed on the Nasdaq. With a market capitalization of $890 million, UroGen Pharma Ltd. is a small-cap company. The stock currently trades at $19.02, down 12.35% today, with a 52-week range of $3.42–$30.00. The company trades at a forward P/E of 13.5x.

Earnings Per Share (Annual · SEC XBRL)

Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.

Fiscal YearEPS DilutedEPS BasicYoY
2025$-3.19-298.7%
2024$-0.80+77.5%
2023$-3.55+26.2%
2022$-4.81
2021
2020
2019
2018

Annual Reports (10-K) · 8 filings

Report DateFiledAccession Number
2025-12-312026-03-020001437749-26-006234SEC ↗
2024-12-312025-03-100001437749-25-006842SEC ↗
2023-12-312024-03-140001437749-24-007753SEC ↗
2022-12-312023-03-240001437749-23-007710SEC ↗
2021-12-312022-03-210001437749-22-006778SEC ↗
2020-12-312021-03-180001564590-21-014016SEC ↗
2019-12-312020-03-020001564590-20-007970SEC ↗
2018-12-312019-02-280001564590-19-005323SEC ↗